April 2, 2015
Mitsubishi Tanabe Pharma Corporation (MTPC) said on April 1 that it entered into a license agreement with Neurocrine Biosciences of the US on March 31 for exclusive rights to develop and commercialize the vesicular monoamine transporter type 2 (VMAT2) inhibitor...read more